Determination of Pt in biological fluids with ICP-MS: Evaluation of analytical uncertainty

Estimation of the uncertainty associated with analytical methods is necessary in order to establish comparability of the results. Methods of Pt determination in biological fluids very often lack of information about the uncertainty of results. This has implications when results are used to interpret the mechanism of platinum compounds, or when the results are considered to optimize clinical therapies. An ICP-MS method for the determination of Pt in biological fluids (plasma, ultrafiltrate, and urine) of patients treated with antitumor agents has been developed and validated. The limits of quantification (LOQ) in the three matrices were 1.0, 0.1, and 2.0 mug L-1, respectively. Intra-day and inter-day precision and accuracy were in good agreement with the FDA criteria for validation of the analytical methods. The validation study was implemented by assessing the uncertainty evaluation for Pt determination in the different matrices according to the EURACHEM/CITAC Guide.